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1 After all, patients with HER-2 overexpression are treated with chemotherapy and trastuzumab, those with luminal A receive endocrine therapy alone, and those with triple-negative breast cancers are offered cytotoxic drugs. In addition, the risks associated with SLNBx, albeit small, include bleeding, pain, seroma, infection, and allergic reaction to the dye used. At first view, avoiding SLNBx makes a whole lot of sense since we know that nodal sampling only helps stage the patient, not improve survival.
Knowing the status of the node(s), however, does help determine whether additional chemotherapeutic regimen is necessary. We do know that node-positive patients are a highrisk group and that they do benefit from having taxanes added to their standard chemotherapeutic regimen. Multiple clinical trials as well as several meta-analyses have substantiated this.
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A meta-analysis of 14 randomized phase III trials of over 25,000 patients confirmed that patients receiving docetaxelcontaining regimen had improved disease-free survival and overall survival over non-docetaxel-containing regimen in node-positive patients.
2, 5 The 2012 Early Breast Cancer Trialists' Collaborative Group meta-analysis of 100,000 women in 123 randomized trials of adjuvant chemotherapy also reported that compared to non-taxane anthracycline regimen, the taxane plus anthracycline regimen resulted in a significant eight-year relative risk reduction of recurrence and breast cancer mortality by 16% and 14%, respectively, which translates to an absolute benefit of 4.6% and 2.8% for reduction of breast cancer recurrence and breast cancer mortality, respectively. 3, 5 In another recent trial by Tolaney et al. 6 , excellent outcomes are reported by de-escalating therapy (with weekly paclitaxel and herceptin for 12 weeks followed by 3-weekly Herceptin for total 1 year) in patients with tumor size #3 cm and negative nodes. Up to 30% of patients with T1 lesions have nodal involvement. 7 Without SLNBx information, these patients would have been understaged and possibly undertreated and sometimes could be overtreated. To our knowledge, we are not aware of any compelling trial that demonstrate that taxanes can be omitted from a subset of patients with node-positive disease.
One might argue that the above trials were old and failed to take into account current knowledge of molecular basis of breast cancer. After all, breast cancer is a molecularly heterogeneous disease that can be grouped into distinct subtypes and that classifying these subtypes can help tailor treatment. 8 Studies have found that hormone receptor (HR)-enriched tumors such as the luminal A and luminal B are not likely to respond to chemotherapy 9, 10 and that the excellent prognosis of luminal A has led many to question the role of chemotherapy. Therefore, what useful information can be gained from sentinel lymph nodes (SLNs)? However, a closer appraisal of the literature reveals that the picture is not as clear-cut. Two published randomized trials, the Breast Cancer International Research Group 001 and the PACS 01, 11, 12 and the pooled analysis of these trials 13 have found that there is not only a subset of estrogen receptor (ER)-positive cancers that are highly sensitive to chemotherapy but there is also no interaction between ER status and docetaxel efficacy. In other words, one cannot discount the role of chemotherapy for a subset of patients with HR-positive tumors since they do benefit equally with chemotherapy as those with HR-negative tumors. The subset that will derive most benefit by chemotherapy will be clarified from results of ongoing prospective trial -TAILORx. 14 The exciting results of the recently reported TAILORx found that patients belonging to the specified low-risk cohort (low recurrence score of 0-10 based on the Oncotype DX® platform) can safely forgo chemotherapy, this applies mainly to those with HR-positive, node-negative tumors.
14 Of course, how else would one begin to select such a patient without performing an SLNBx?
What if the same platform is applied to identify a subset of low-risk node-positive patients? The ongoing RxPONDER trial 15 (utilizes the Oncotype DX® platform) and MINDACT 16 (utilizes MammaPrint 70-Gene Breast Cancer Recurrence Assay) are doing exactly the same. Women with not only HR-positive tumors but also node-positive tumors are enrolled, and if the results of the RxPONDER mirror those of the TAILORx trial, then, indeed the days of SLNBx are numbered. But even so, one must be cognizant that these trials are restricted only to those with HR-positive tumors, a group that makes up roughly 60% of women below the age of 50 years and 80% of those above the age of 50 years. 17 What approach should one employ for the other 20%-40% of patients with HR-negative tumors?
The American College of Surgeons Oncology Group Z0011 (ACOSOG Z0011) trial 18 demonstrated that in patients with clinically node-negative axilla with T1-T2 tumors, 1-2 positive SLNs, whole breast radiation and systemic therapy can replace axillary lymph node dissection (ALND) in preventing axillary recurrence in patients with macrometastatic and micrometastatic SLNs. These results only tell us whether ALND is needed following a positive SLNBx, and not whether SLNBx is necessary. To answer such a question, we would need to know the specific systemic therapy regimen. In other words, we would need to know who received taxanes and who did not and whether the receipt of taxanes really made a whole lot of difference. If we were to discover that there was no significant difference in survival between the two groups, then we could make a compelling argument against SLNBx. Unfortunately, information on specific chemotherapeutic regimen was not specified in the protocol. Perhaps, it might be a worthwhile endeavor to retrospectively analyze such a data from ACOSOG Z0011.
Although axillary ultrasound is widely used in Europe as a standard modality in the preoperative staging of EBC, there is a concern in terms of its reliability when US-guided biopsy results are negative. A 2014 meta-analysis found that one in four women with a US-guided biopsy-proven negative axilla has a positive SLNBx. 19 Currently, there is an ongoing prospec tive multicenter international randomized trial comparing SLNBx with no surgery in the axilla for those with negative ultrasonographic findings (Sentinel node vs. Observation after axillary UltrasouND trial [SOUND trial]). 20 Hopefully, the results from this trial will reconcile some of the concerns raised.
Finally, EBC encompasses a heterogeneous spectrum of diseases, spanning from a tumor measuring less than 2 cm to the one that measures up to 5 cm. In addition, a subset of N1 disease (ie, T0-T2N1) can also be considered as EBC. Neoadjuvant chemotherapy plays an important role for those with large tumor since it increases the rate of breast conserving therapy as demonstrated by NSABP B−27. 21 For those with clinically negative nodes, SLNBx after neoadjuvant chemotherapy is an acceptable procedure. However, SLNBx following neoadjuvant chemotherapy for those with clinically positive axillary lymph nodes is not reliable. ACOSOG Z1071 22 (Alliance trial) and SENTinel NeoAdjuvant 23 (SENTINA) found that the procedure had resulted in a high false-negative rate; in ACOSOG Z1071, the false-negative rate was 12.6%, while it was 18.5% in the SENTINA trial. Most of the EBC studies, challenging old paradigms (including SOUND trial), are conducted in a highly select group of patients, mainly those with T1 tumors. In fact, 67%-71% of patients in the ACOSOG Z0011 trial had T1 disease and 80% of those in the AMAROS 24 trial had T1 disease. Will results from these studies also be applicable to those with stage II diseases?
We have come a long way since the days of performing a Halstedian radical mastectomy. The medical and surgical community has made major strides in improving the lives of thousands of patients as we learn more about the biology of breast cancer. Perhaps the day will come when SLNBx will be of historic interest. However, given the clinically important information that can be gained from SLNBx and the low risk associated with the procedure, we remain reluctant to abandoning it at this point of time. 
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